Zobrazeno 1 - 10 of 28 pro vyhledávání: '"Masato Komai"'
1
Akademický článek
Nuclear SphK2/S1P signaling is a key regulator of ApoE production and Aβ uptake in astrocytes
Autor: Masato Komai, Yuka Noda, Atsuya Ikeda, Nanaka Kaneshiro, Yuji Kamikubo, Takashi Sakurai, Takashi Uehara, Nobumasa Takasugi
Publikováno v: Journal of Lipid Research, Vol 65, Iss 3, Pp 100510- (2024)
The link between changes in astrocyte function and the pathological progression of Alzheimer's disease (AD) has attracted considerable attention. Interestingly, activated astrocytes in AD show abnormalities in their lipid content and metabolism. In p
Externí odkaz: https://doaj.org/article/db7691086d1a4bb783bf0877efa1111a
Zobrazit plný text záznamu
2
Akademický článek
Lipid flippase dysfunction as a therapeutic target for endosomal anomalies in Alzheimer’s disease
Autor: Nanaka Kaneshiro, Masato Komai, Ryosuke Imaoka, Atsuya Ikeda, Yuji Kamikubo, Takashi Saito, Takaomi C. Saido, Taisuke Tomita, Tadafumi Hashimoto, Takeshi Iwatsubo, Takashi Sakurai, Takashi Uehara, Nobumasa Takasugi
Publikováno v: iScience, Vol 25, Iss 3, Pp 103869- (2022)
Summary: Endosomal anomalies because of vesicular traffic impairment have been indicated as an early pathology of Alzheimer’| disease (AD). However, the mechanisms and therapeutic targets remain unclear. We previously reported that βCTF, one of th
Externí odkaz: https://doaj.org/article/124f74c73d5442159b8dfea2961c3d7f
Zobrazit plný text záznamu
3
Akademický článek
The Pursuit of the 'Inside' of the Amyloid Hypothesis—Is C99 a Promising Therapeutic Target for Alzheimer’s Disease?
Autor: Nobumasa Takasugi, Masato Komai, Nanaka Kaneshiro, Atsuya Ikeda, Yuji Kamikubo, Takashi Uehara
Publikováno v: Cells, Vol 12, Iss 3, p 454 (2023)
Aducanumab, co-developed by Eisai (Japan) and Biogen (U.S.), has received Food and Drug Administration approval for treating Alzheimer’s disease (AD). In addition, its successor antibody, lecanemab, has been approved. These antibodies target the ag
Externí odkaz: https://doaj.org/article/49bd45343bc04324a3273f88ddec50c2
Zobrazit plný text záznamu
4
Akademický článek
A Novel CC-Chemokine Receptor 3 Antagonist, Ki19003, Inhibits Airway Eosinophilia and Subepithelial/Peribronchial Fibrosis Induced by Repeated Antigen Challenge in Mice
Autor: Masato Komai, Hiroyuki Tanaka, Koichi Nagao, Masayuki Ishizaki, Daisuke Kajiwara, Toru Miura, Hiroshi Ohashi, Tomoko Haba, Kazuki Kawakami, Eiji Sawa, Osamu Yoshie, Naoki Inagaki, Hiroichi Nagai
Publikováno v: Journal of Pharmacological Sciences, Vol 112, Iss 2, Pp 203-213 (2010)
CC-chemokine receptor 3 (CCR3) is a chemokine receptor for which major ligands, CC-chemokine ligand (CCL) 11, CCL24, and CCL26, are known to be involved in chemotaxis for eosinophils. In the present study, we evaluated the effect of a low molecular w
Externí odkaz: https://doaj.org/article/81343e8e47f946f7bd423ca42ef55b94
Zobrazit plný text záznamu
5
A novel monoclonal antibody with improved FcγR blocking ability demonstrated non-inferior efficacy compared to IVIG in cynomolgus monkey ITP model at considerably lower dose
Autor: Yuko Nakajima-Kato, Masato Komai, Tadashi Yoshida, Akiko Kanai
Publikováno v: Clinical and experimental immunology.
Intravenous immunoglobulin (IVIG) is a well-established treatment for various autoimmune and inflammatory diseases. However, the standard dose prescribed for autoimmune diseases, including immune thrombocytopenic purpura (ITP), is 2 g/kg, which is ma
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1841fb17e6a517cb629dd4b8a52074b0
https://pubmed.ncbi.nlm.nih.gov/36480334
Zobrazit plný text záznamu
6
Lipid flippase dysfunction as a novel therapeutic target for endosomal anomalies in Alzheimer’s disease
Autor: Tadafumi Hashimoto, Takashi Sakurai, Yuji Kamikubo, Nobumasa Takasugi, Takashi Uehara, Ryosuke Imaoka, Masato Komai, Atsuya Ikeda, Takeshi Iwatsubo, Nanaka Kaneshiro
β-amyloid precursor protein (APP) and their metabolites are deeply involved in the development of Alzheimer’s disease (AD). Upon the upregulation of β-site APP cleaving enzyme 1 (BACE1), its product, the β-carboxyl-terminal fragment of APP (βCT
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b4d1d68525d0bdbeba0ff3e665d42fa3
https://doi.org/10.1101/2021.07.30.454423
Zobrazit plný text záznamu
8
Discovery and mechanistic study of thiazole-4-acylsulfonamide derivatives as potent and orally active ChemR23 inhibitors with a long-acting effect in cynomolgus monkeys
Autor: Takamichi, Imaizumi, Shigeki, Otsubo, Michihiro, Maemoto, Atsuko, Kobayashi, Masato, Komai, Hidenori, Takada, Yumi, Sakaida, Nobumasa, Otsubo
Publikováno v: Bioorganic & Medicinal Chemistry. 56:116587
Plasmacytoid dendritic cells (pDCs) are a subset of dendritic cells that can secrete large amounts of type I interferon. ChemR23, a G protein-coupled receptor (GPCR) expressed on the surface of pDCs, contributes to the recruitment of pDCs to inflamed
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d6a57426849d99a48ac3d2533600346
https://doi.org/10.1016/j.bmc.2021.116587
Zobrazit plný text záznamu
10
The discovery and optimization of a series of 2-aminobenzoxazole derivatives as ChemR23 inhibitors
Autor: Shigeki Otsubo, Takamichi Imaizumi, Megumiko Magara, Masato Komai, Atsuko Kobayashi, Nobumasa Otsubo
Publikováno v: Bioorganicmedicinal chemistry. 27(21)
A structural class of 2-aminobenzoxazole derivatives possessing biphenyltetrazole was discovered to be potent human ChemR23 inhibitors. We initially tried to improve the potency of compound 1, which was found through in-house screening using the huma
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a3b47b0485c05655e69195caf65913ee
https://pubmed.ncbi.nlm.nih.gov/31521459
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje